AcelRx Pharma (ACRX) Reports In-Line Q2 EPS

AcelRx Pharma (NASDAQ: ACRX) reported Q2 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $818 thousand versus the consensus estimate of $910 thousand.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Limoneira sells vineyard property for $15M at public auction
• Aon names interim CFO as Edmund Reese exits the firm